NeurogesX Reports Third Quarter 2011 Results
October 31, 2011 16:05 ET
|
NeurogesX
Recent Highlights:
Qutenza® (capsaicin) 8% patch U.S. launch progress includes:
Sales of Qutenza to end user customers reached $1.0 million in 3Q11, an increase of 22% over...
NeurogesX Appoints Dr. Stephen J. Peroutka as Executive Vice President and Chief Medical Officer
October 31, 2011 08:30 ET
|
NeurogesX
SAN MATEO, Calif., Oct. 31, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today...
NeurogesX to Hold Conference Call to Discuss Third Quarter 2011 Results
October 27, 2011 10:10 ET
|
NeurogesX
SAN MATEO, Calif., Oct. 27, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today...
NeurogesX Announces Resignation of EVP of Research and Development and Chief Medical Officer Jeffrey K Tobias, MD
September 27, 2011 08:30 ET
|
NeurogesX
SAN MATEO, Calif., Sept. 27, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced...
NeurogesX Submits Supplemental New Drug Application for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)
September 08, 2011 08:30 ET
|
NeurogesX
Received U.S. FDA Orphan Drug and Fast Track Designations for the Potential Use of Qutenza to Treat Painful HIV-PN
Qutenza Currently Approved by U.S. FDA for the Management of Neuropathic...
NeurogesX to Participate in Two Investor Healthcare Conferences in September 2011
September 01, 2011 17:43 ET
|
NeurogesX
SAN MATEO, Calif., Sept. 1, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced...